CNS Pharmaceuticals (CNSP) Expected to Announce Quarterly Earnings on Monday

CNS Pharmaceuticals (NASDAQ:CNSP) is expected to post its Q2 2026 results before the market opens on Monday, August 17th. Analysts expect CNS Pharmaceuticals to announce earnings of ($0.24) per share for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 21, 2026 at 9:30 AM ET.

CNS Pharmaceuticals (NASDAQ:CNSP) last posted its earnings results on Thursday, May 14th. The company reported ($7.30) earnings per share for the quarter, beating the consensus estimate of ($8.82) by $1.52.

CNS Pharmaceuticals Price Performance

CNS Pharmaceuticals stock opened at $5.24 on Monday. The firm has a 50 day simple moving average of $4.95 and a 200-day simple moving average of $4.21. The stock has a market cap of $7.65 million, a price-to-earnings ratio of -0.18 and a beta of 3.05. CNS Pharmaceuticals has a 1-year low of $1.90 and a 1-year high of $10.59.

Insiders Place Their Bets

In related news, Director Faith L. Charles purchased 7,100 shares of the company’s stock in a transaction on Monday, May 18th. The stock was acquired at an average cost of $4.79 per share, for a total transaction of $34,009.00. Following the completion of the transaction, the director directly owned 7,100 shares in the company, valued at approximately $34,009. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 0.01% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CNS Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Armistice Capital LLC purchased a new position in shares of CNS Pharmaceuticals during the second quarter worth $335,000. Ikarian Capital LLC purchased a new stake in shares of CNS Pharmaceuticals in the 4th quarter valued at $241,000. Finally, Boothbay Fund Management LLC purchased a new stake in shares of CNS Pharmaceuticals in the 4th quarter valued at $71,000. Hedge funds and other institutional investors own 14.02% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $20.00.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.